Nicht an der Qualität sparen. Mit Anlagelösungen der Landesbank Baden-Württemberg. Jetzt mehr erfahren -Werbung-
06.10.2023 07:30:06

Spexis to host business update conference call on October 9, 2023

Spexis AG / Key word(s): Statement
Spexis to host business update conference call on October 9, 2023

06.10.2023 / 07:30 CET/CEST


 

 

Spexis to host business update conference call on October 9, 2023

 

Allschwil, Switzerland, October 6, 2023

 

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT.

Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details:

France: +33 0805102207
Germany: +49 0800-6647650
Italy: +39 800897553
Switzerland +41 0800-002063
United Kingdom +44 08082389064
United States +1 877-317-6789

International Toll Free +1 412-317-6789

 

Event Title: Spexis AG Business Update Conference Call
 

The conference call will also be available via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=6s6eCE7g

After the call, a replay of the webcast will be available via the above link.

 

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.

 

For further information please contact:

For Investors: 
 
Hernan Levett
Chief Financial Officer
Spexis AG.
+41 61 567 16 00
IR@spexisbio.com

Or

Stephen Jasper
Managing Director
Gilmartin Group
stephen@gilmartinir.com

 

For Media: 
 
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch

 

 



End of Media Release


Language: English
Company: Spexis AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone: +41 61 567 1600
Fax: +41 61 567 1601
E-mail: info@spexisbio.com
Internet: www.spexisbio.com
ISIN: CH0106213793
Valor: SPEX
Listed: SIX Swiss Exchange
EQS News ID: 1742821

 
End of News EQS News Service

1742821  06.10.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1742821&application_name=news&site_id=smarthouse

Analysen zu Spexis Ltd. (ex Polyphor)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Spexis Ltd. (ex Polyphor) 10,36 4,23% Spexis Ltd. (ex Polyphor)